



TRIDENT LIFELINE LIMITED
(Formerly Trident Lifeline Private Limited)

CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

Date: November 26, 2024

BSE Limited 14th Floor, P. J. Towers, Dalal Street, Fort, Mumbai - 400001.	Stock ID: TLL Scrip Code: 543616
--	---

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Acquiring 51% stake and making a Subsidiary

Ref: Our intimation letter dated May 02, 2024

Dear Sir/Ma'am,

In continuation of our earlier intimation letter dated May 02, 2024 and pursuant to Regulation 30 of the SEBI Listing Regulations, we would like to inform that the Board of Directors of the Company had proposed to acquire additional 50.49% of share of **TLL PARENTERALS LIMITED ("TPL")** (CIN: U21001GJ2023PLC146963) by way of new allotment of equity shares, resulting to 51% post acquisition holding and making TPL as a subsidiary of the Company.

Pursuant to BSE Notice No. 20230714-34 dated July 14, 2023, occurrence of the above event/information is on November 26, 2024 at 06:00 p.m.

Further, the information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith.

The board meeting was commenced at 06:00 p.m. and concluded at 06:30 p.m.

Thanking you,

For Trident Lifeline Limited

NIKITA SHARMA
COMPANY SECRETARY AND COMPLIANCE OFFICER
M. NO.: A60595

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.
Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.
Tel : +91 261 2490224, 2490225

Information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	<p>TLL PARENTERALS LIMITED (CIN: U21001GJ2023PLC146963) Company incorporated under the provisions of the Companies Act, 2013, having its Registered Office in Surat, Gujarat.</p> <p>Capital Details: Authorized Share Capital: Rs. 3,00,00,000/- divided into 30,00,000 Equity Shares of Rs.10/- each</p> <p>Paid-up Share Capital: Rs. 1,00,00,000/- divided into 10,00,000 Equity Shares of Rs.10/- each</p> <p>Turnover: NIL (Incorporated on December 15, 2023 and yet to commence business)</p>
2	whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p>Yes, TLL Parenterals Limited (TPL), a public Limited Company in which Mr. Hardik Jigishkumar Desai is member cum director and Mr. Shravan H Patel and Mr. Chetan Chandrakant Jariwala (director's Relative) are director and all of above are part of promoters/promoter group/board of acquiring Company i.e being Trident Lifeline Limited (The Company), have an interest in the entity being acquired (TPL). The transaction is being undertaken on an arm's length basis.</p>
3	Industry to which the entity being acquired belongs	Pharmaceuticals and Chemical Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its	This acquisition would allow the company to partner with the leading and fast-growing market of organic and inorganic chemicals along with pharmaceuticals and allied products.

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

	business is outside the main line of business of the listed entity)	
5	Brief details of any governmental or regulatory approvals required for the acquisition.	The acquisition is within the overall limit approved by the Shareholders of the Company under Section 186 of the Companies Act, 2013.
6	Indicative time period for completion of the acquisition	Approx. One Month
7	Consideration - whether cash consideration or share swap and details of the same;	Subscription of shares is by way of Cash
8	Cost of acquisition or the price at which the shares are acquired;	Rs 10/- per share (face value)
9	Percentage of shareholding / control acquired and / or number of shares acquired;	<p>Pre-acquisition holding: 5,100 equity share of Rs. 10 each amounting of Rs. 51,000 /- constituting 0.51% equity stake</p> <p>Proposed Acquisition: 11,22,000 equity shares of Rs 10/- amounting of Rs. 1,12,20,000/-</p> <p>Post-acquisition holding: 11,27,100 equity shares of Rs 10/- amounting of Rs. 1,12,71,000/- constituting 51% equity stake</p>
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Date of incorporation: December 15, 2023</p> <p>Product/line of business: Pharmaceuticals and Chemical Industry</p> <p>Last 3 years' turnover: NA (incorporated in the current year)</p> <p>Presence of entity: India</p>